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Objective: This survey of published researchers of long-acting reversible contraceptives (LARCs) examines their opinions about important
barriers to LARC use in the United States (US), projections for LARC use in the absence of barriers and attitudes toward incentives for
clinicians to provide and women to use LARC methods.
Study design: We identified 182 authors of 59 peer-reviewed papers on LARC use published since 2013. A total of 104 completed an
internet survey. We used descriptive and multivariate analyses to assess LARC use barriers and respondent characteristics associated with
LARC projections and opinions.
Results: The most commonly identified barrier was the cost of the device (63%), followed by women’s knowledge of safety, method
acceptability and expectations about use. A shortage of trained providers was a commonly cited barrier, primarily of primary care providers
(49%). Median and modal projections of LARC use in the absence of these barriers were 25–29% of contracepting women. There was
limited support for provider incentives and almost no support for incentives for women to use LARC methods, primarily out of concern
about coercion.
Conclusions: Clinical and social science LARC experts project at least a doubling of the current US rate of LARC use if barriers to method
provision and adoption are removed. While LARC experts recognize the promise of LARC methods to better meet women’s contraceptive
needs, they anticipate that the majority of US women will not choose LARC methods. Reducing unintended pregnancy rates will depend on
knowledge, availability and use of a wider range of methods of contraception to meet women’s individual needs.
Implications: Efforts to increase LARC use need to meet the dual goals of increasing access to LARC methods and protecting women’s
reproductive autonomy. To accomplish this, we need reasonable expectations for use, provider training, low-cost devices and noncoercive
counseling, rather than incentives for provision or use.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).Keywords: Intrauterine contraceptives; Contraceptive implant; Projection; Barrier to use; Policy recommendations1. Introduction
Intrauterine contraceptives (IUDs) and contraceptive
implants, also known as long-acting reversible contraception
[long-acting reversible contraceptive (LARC)], are the most
effective reversible forms of contraception [1]. In 2002, 15%
of women worldwide who were married or in a union used a
LARC method, primarily IUDs, second only in popularity to
sterilization [2]. In that same year, only 2% of contracepting⁎ Corresponding author.
E-mail address: fosterd@obgyn.ucsf.edu (D.G. Foster).
http://dx.doi.org/10.1016/j.contraception.2015.10.003
0010-7824/© 2015 The Authors. Published by Elsevier Inc. This is an open a
org/licenses/by-nc-nd/4.0/).women in the United States (US) were using a LARC
method [3]. Since then, there has been a large push in the
medical and public health communities in the US to increase
the availability and adoption of IUDs and implants [4,5] to
reduce the persistently high unintended pregnancy rate, as
well as the costs associated with these pregnancies [6–9]. In
2007, the American College of Obstetricians and Gynecol-
ogists published Committee Opinions highlighting IUDs and
implants for their potential to reduce unintended pregnancy
and recommending them as a first-line option for adolescents
and later, in 2009, as a first-line option for nearly all women
[10–13]. In 2010, the Centers for Disease Control and
Prevention released the US Medical Eligibility Criteria forccess article under the CC BY-NC-ND license (http://creativecommons.
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use of these methods is considered safe [14]. Most recently,
the American Academy of Pediatrics joined other organiza-
tions in recommending LARC as a first-line contraceptive
option [15]. During this time, the scientific literature has seen
a tremendous growth in scholarship related to LARC access
and clinical care, as well as provider and patient knowledge,
acceptability and use.
Several national and local initiatives and training
programs were launched in the mid to late 2000s with the
specific aim of promoting LARC use. Initiatives in Colorado
and Iowa made a concerted effort to reduce unintended
pregnancy through increased investments in IUD and
implant provision that included training providers, funding
marketing and media campaigns and reducing the cost of
devices [16–18]. In the Contraceptive Choice Project in St.
Louis, provision of free IUDs and implants combined with
counseling designed to promote their use resulted in
large-scale adoption of LARC methods [19]. In California,
an IUD provider training program for providers enrolled in
the state’s Medicaid family planning program resulted in
increased provision of IUDs at sites that participated in the
training [20]. A national cluster randomized trial recently
had success in training providers on IUD and implant
provision at 40 reproductive health clinics across the US
[21]. These programs have demonstrated a reduction in
unintended pregnancies, abortions and teen births due to
increased use of LARC methods [16,18,19,21].
Due in part to these policy recommendations and LARC
promotion programs, there has been a steady growth in
women’s use of IUDs and implants across a range of
demographic groups, including adolescents and nulliparous
women across the US [22,23]. By 2011–2013, 7% of
reproductive-age women in the US were using an IUD or
implant, representing a nearly 5-fold increase since 2002 [23].
The data also suggest that LARC use varies substantially
by population subgroups. In the US, the greatest proportion
of users is ages 25–35 years and parous [23]. A survey of
female family planning providers in the US demonstrated
that 42% used a LARC method and as many as 75% of
women enrolled in the St. Louis program chose an IUD or
implant [19,24]. Moreover, while there have been substantial
increases in LARC use nationally, some other countries and
regions have much higher rates of LARC use than we have
currently in the US — 43% in Central Asia, 41% in China,
27% in Norway and 19% in France [25].
While there is widespread consensus that access to LARC
methods is an important public health goal, the intense focus
of some policies and programs on LARC methods over other
methods has led some medical and public health experts to
voice concern about potential coercion if women are forced
to adopt a method that does not match their own preferences
or that they do not want and cannot discontinue without
clinical intervention [26–29].
The current study surveys LARC experts about their
views about the future of LARC use and promotion in theUS. We present their assessment of the barriers to greater
LARC use, projections of LARC use in the absence of these
barriers and opinions of current and proposed LARC
promotion policies.2. Methods
In March 2015, we conducted an electronic PubMed
search of all peer-reviewed research articles that contained
any of four search terms (Long Acting Reversible Contra-
ception, High Efficacy Reversible Contraception, Intrauter-
ine Device and Implant) published since 2013 in three
journals that have strong coverage of contraceptive research
(Obstetrics and Gynecology, Perspectives on Sexual and
Reproductive Health and Contraception). We excluded
editorials, conference abstracts, case reviews, articles
unrelated to IUDs and implants, and research articles
whose focus was solely on physiology or women outside
the US. After retrieving our final set of articles, we searched
for all authors’ email addresses, first looking for contact
information within the article, then using directory searches
within each author’s institution, searching for contact
information in other articles written by this author and
finally, for email addresses we still had not found, doing a
Google search for the author.
On July 9, 2015, an email inviting these authors to
complete a 5-minute online survey in Qualtrics about
projections for LARC use and opinions about LARC
promotion was sent and signed by the study authors Diana
Greene Foster and Antonia Biggs. We asked respondents to
complete the survey within 2 weeks. We sent one reminder
at 1 week following the survey launch and a final reminder at
2 weeks. Each email had a unique link so that respondents
could complete the survey only once. Respondents received
no compensation for participating.
The survey asked respondents to identify the top five
factors that prevent women from using LARC methods in the
US. The list of possible barriers was identified through a
review of the literature [30–35]. An open text box was
provided for comments or additional barriers.
The second question asked participants to estimate the
percentage of contracepting women in the US that would be
LARC users if all the barriers listed in the first question were
removed. A range was given in 5% increments from 0% to
100%. Labels were added at 10–14% “similar to current,”
25–29% “similar to France and Norway,” 40–44% “similar
to female family planning providers in the US” and 75–79%
“similar to women presenting for a new contraceptive
method at the Choice Project of Saint Louis”. Research
supporting each labeled data point was cited below the list.
Again, an open text box allowed respondents to provide
comments.
The third set of questions solicited respondents’ opinions
about specific incentives for LARC placement. We describe
goals and financial incentives as follows: “some health plans,
able 1
haracteristics of respondents.
Number Percentage
n=104 100%
ge (years)
b30 1 1%
30–39 42 40%
40–49 28 27%
50–59 15 14%
60–69 11 11%
70–79 3 3%
Missing 4 4%
ender
Female 80 77%
Male 21 20%
Missing 3 3%
ace/ethnicity
White 89 86%
Hispanic/Latina 9 9%
Black/African American 2 2%
Asian 8 8%
Other 1 1%
Missing 3 3%
ighest degree
MD 45 43%
PhD/DrPH 34 33%
RN/NP/PA 2 2%
MA/MPH 20 19%
Missing 3 3%
stitutional affiliation
University 75 72%
Hospital 24 23%
Family planning clinic 24 23%
Research organization 21 20%
Other 14 13%
Primary care clinic 9 9%
Missing 3 3%
esearcher type
Clinician placing LARC 38 37%
Clinician not placing LARC 9 9%
Nonclinicians 54 52%
Missing 3 3%
ontraceptive use and risk for pregnancy
IUD 30 29%
Implant 1 1%
Another method 25 24%
No method but at risk 7 7%
Not at risk of pregnancy 37 36%
Missing 4 4%
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to encourage LARC placement. An example of a financial
incentive would be when a health plan or funding agency
pays a clinic an additional amount of money if clinicians
place LARC in a certain fraction of patients. An example of a
goal would be when a health plan or funding agency
publicizes a desirable LARC placement rate but does not link
payment to whether the placement rate is achieved.”We then
asked the respondent how much they agreed or disagreed
(strongly agree, agree, neither agree nor disagree, disagree or
strongly disagree) with each of three statements:
(1) Health plans and funding agencies should use a
minimum threshold goal (such as 1% of women in a
clinic receiving LARC) to confirm that LARC
methods are available.
(2) Health plans and funding agencies should use a
higher LARC placement goal to encourage clini-
cians to place more LARC methods.
(3) Health plans, funding agencies and clinics should
use financial incentives to encourage clinicians to
place LARC methods.
If they agreed or strongly agreed with the second item,
they were asked to indicate in an open text field what
placement rate they thought would be reasonable.
The fourth set of questions asked about specific
incentives for women to adopt LARC methods. We provided
some background information: “some state bills have
proposed offering women incentives for using a LARC
method. Examples of these individual incentives include
access to welfare benefits or reductions in jail sentences for
women who agree to use a LARC method. Some programs
have offered to pay women, for example, illicit drug users, to
use a LARC method.” We then asked them to indicate how
much they agreed or disagreed with five statements:
(1) Public assistance programs should be able to restrict
benefits if a woman does not use a LARC method.
(2) Corrections agencies should be able to offer
reduced jail time if a woman uses a LARC method.
(3) Women receiving public assistance should have
access to all methods of contraception for free.
(4) Women receiving public assistance should have
access to free LARC methods but not to less
effective methods for free.
(5) It is appropriate for programs to pay women to use a
LARC method.
After each set of questions about provider incentive
policies and policies aimed at women, we provided an open
text box for comments. For the Likert scale policy opinion
questions, we score the responses as follows: −2, strongly
disagree; −1, disagree; 0, neither agree nor disagree; +1,
agree; and +2, strongly disagree. This scoring enabled us to
calculate meaningful averages.T
C
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R
CFinally, we asked respondents about themselves — their
age, whether they identify as female or male, their race/
ethnicity (check all that apply), any institutional affiliations
(university, a family planning clinic, a primary care clinic, a
hospital, a research organization, other) and the highest
degree they have earned. For respondents who reported
clinical degrees, we asked their medical specialty, whether
they are currently in clinical practice and, if in clinical
practice, whether they routinely place LARC methods.
Finally, we asked whether they or their partners use a LARC
method of contraception where the answer categories were as
follows: yes, we use an IUD; yes, we use an implant; no, I am
Table 2
Percentage of respondents endorsing each barrier.
Barrier Number Percentage
Cost of the device to women 65 63%
Lack of information about safety and acceptability 63 61%
Fear of side effects 58 56%
Concern about having the device placed 53 51%
Lack of trained primary care providers 51 49%
Lack of insurance coverage for the device 49 47%
Requirement for multiple visits 35 34%
Lack of knowledge about efficacy 30 29%
Stocking challenges 26 25%
Low reimbursement rates for providers 20 19%
Billing challenges 20 19%
Lack of trained family planning providers 16 15%
Concern about being able to get the device removed 15 14%
Unnecessary screening tests 5 5%
546 D.G. Foster et al. / Contraception 92 (2015) 543–552not at risk of pregnancy or causing pregnancy; no, we use
another contraceptive method; and no, we do not use any
contraceptive method and are at risk of pregnancy.
For analysis, we combined ages into groups of roughly
equal thirds (b40 years, ages 40–49 years and 50 years or
more). We created a variable researcher type that distin-
guishes clinicians who currently place LARC, clinicians who
do not place LARC or are not in clinical practice and
nonclinician researchers. We tested differences by age,
gender and researcher type in endorsement of specific
barriers using chi-square tests. We used a multiple linear
regression to detect how three respondent characteristics
(age, gender and researcher type) are associated with
projections for future LARC use in the US if the major
barriers to use were removed. In multivariate logistic
regression models, we examined predictors (age group,
gender and researcher type) of agreement (agree or strongly
agree) with eight statements about incentives for providers to
place or women to adopt LARC methods. All data were
analyzed in STATA version 12.3. Results
Our search identified 121 research articles about LARC
methods published between January 2013 and March 2015.
We excluded 43 articles because they were entirely about
physiology (e.g., hemoglobin measurement prior to place-
ment of copper IUDs, vaginal microbiome changes after
hormonal IUD use or trials of analgesics for insertion) and
another 19 because they focused on populations outside the
US. The remaining 59 articles listed a total of 182 authors;
we found email addresses for 173 (95%). Of these, we were
unable to reach 19 authors — 14 had “undeliverable” email
addresses and 5 sent back vacation messages indicating that
they were not checking mail during our survey period.
Among the 154 authors for whom the survey introduction
was successfully delivered, 104 (68%) participated in oursurvey, representing 57% (104/182) of all eligible authors.
One hundred completed all the questions; four completed all
questions except the questions about personal characteristics.
Most respondents were in their thirties and forties (40%
and 27%, respectively); 28% were age 50 years or older.
Three quarters (77%) of respondents identified as female.
The vast majority (86%) reported being white with few
reporting any other race/ethnicities (9 Hispanic, 2 Black/
African American and 8 Asian). In terms of highest degrees
earned, 43% reported having an MD, one third a PhD or
DrPH, 19% reported a having a Master’s degree and 2%
reported earning nursing degrees (NP/RN/CNM/CNS).
Among the 47 participants with a clinical degree, three
quarters reported a specialty in Obstetrics and Gynecology;
14% reported Family Medicine. Nearly all (91%) of
clinicians were currently in clinical practice and 93% of
those reported regularly placing LARC methods for their
patients. Combining degree and clinical practice into a
researcher type variable, we found that 37% were clinicians
regularly placing LARC, 9% were clinicians who are not
placing LARC and 52% were nonclinician researchers.
Almost three quarters of respondents were affiliated with a
university, one quarter with a hospital, one quarter with a
family planning clinic, 9% with a primary care clinic and
20% with a research organization. As for personal LARC
use, one third were not at risk of pregnancy or causing
pregnancy. Among those at risk of pregnancy, half reported
using a LARC method (30 IUD and 1 implant), 40% using
another method of contraception and 11% reported using no
method of contraception (see Table 1).
3.1. Barriers to greater LARC use in the US
When asked to select the top five factors that prevent
women from using LARC methods in the US, the most
commonly identified barrier was the cost of the device for
women (63%). The next three most common, each selected
by over half of respondents, had to do with women’s
knowledge of safety, acceptability of the method and
expectations about use (side effects and placement). A
shortage of trained providers was a commonly cited barrier,
although more for primary care providers (49%) than for
family planning providers (15%). We find no statistically
significant differences in endorsement of any specific
barriers by age or gender or whether the respondent was a
LARC placing clinician, a non-LARC placing clinician or a
nonclinician researcher (see Table 2).
Additional barriers were mentioned by respondents in the
open text field. Several pointed to a lack of counseling about
LARC methods, for example, “provider counseling is an
important factor not explicitly mentioned here. Do they see a
provider who is knowledgeable about LARC and suggests
LARC for all patients who are medically eligible and
desiring years of pregnancy protection?” reported a non-
clinician researcher. Others mentioned rationing — either
providers withholding limited devices for only “deserving”
0% 5% 10% 15% 20% 25% 30% 35%
<10%
10-14%
15-19%
20-24%
25-29%
30-34%
35-39%
40-44%
45-49%
50-54%
55-59%
60-64%
65-69%
70-74%
75-79%
80-84%
85-89%
90-94%
95-100%
Projections for LARC use in the United States
similar to current1
similar to France and Norway2
similar to female family planning providers in the U.S.3
similar to women presenting for a new contraceptive method at the Choice Project
of Saint Louis4
Fig. 1. Projections.
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LARC devices a woman can have within a 3- or 5-year
period. One non-LARC placing clinician respondent pointed
out that, in addition to primary care providers and family
planning providers, pediatricians also needed LARC train-
ing, “there are few pediatricians trained to place LARC and
this is a huge issue since we are the primary medical care
providers for adolescent girls.” Several respondents’ com-
ments pointed to the interconnectedness of barriers. For
example, that low reimbursement results in stocking
problems or that shortages of trained providers and billing
problems result in multiple visit requirements. Finally, some
respondents mentioned that women’s contraceptive prefer-
ences also limit use of LARC methods — that there areTable 3
Opinions on policy.
Policies to encourage providers to place LARCs
Health plans and funding agencies should use a minimum threshold goal (such
women in a clinic receiving LARC) to confirm LARC methods are available
Health plans and funding agencies should use a higher LARC placement goal t
clinicians to place more LARC methods.
Health plans, funding agencies and clinics should use financial incentives to en
clinicians to place LARC methods.
Policies to encourage women to use LARCs
Public assistance programs should be able to restrict benefits if a woman does
LARC method.
Corrections agencies should be able to offer reduced jail time if a
woman uses a LARC method.
Women receiving public assistance should have access to all methods of contra
for free.
Women receiving public assistance should have access to free LARC methods
to less effective methods for free.
It is appropriate for programs to pay women to use a LARC method.
a The mean score is the weighted average of responses where strongly disagrwomen who “don’t want something inside” their bodies and
women who know the side effects of LARC and do not think
that the side effects are acceptable.
3.2. Projections of LARC use in the US
When asked what percentage of contracepting women
would use a LARC method if all of the barriers listed in the
first question were removed, the median and modal
responses were in the range of 25–29%. Three quarters of
respondents predicted that fewer than 45% of contracepting
women would use a LARC method. Only 2% of respondents
could see no room for increases over our current rate of
LARC use. Just under 6% predicted that the whole countryStrongly
disagree
Disagree Neither agree
nor disagree
Agree Strongly
agree
Mean
scorea
−2 −1 0 1 2
as 1% of
.
14% 20% 17% 35% 15% 0.17
o encourage 19% 26% 18% 26% 12% −0.14
courage 35% 27% 17% 18% 4% −0.70
not use a 83% 15% 2% 0% 0% −1.81
77% 15% 6% 2% 0% −1.67
ception 0% 0% 3% 11% 86% 1.83
but not 68% 23% 5% 2% 2% −1.53
55% 22% 14% 9% 0% −1.24
ee is −2, disagree is −1, neutral is 0, agree is 1 and strongly agree is 2.
Table 4
Results of multivariate logistic regression models.a
Agree or strongly agree that health plans and funding agencies should use a minimum threshold goal
Adjusted odds ratio 95% CI
Age (years) b40 0.46 [0.17, 1.24]
40s Reference
50+ 0.83 [0.28, 2.48]
Sex Male 1.22 [0.42, 3.53]
Female Reference
Researcher type LARC placing clinician 0.77 [0.32, 1.81]
Non-LARC placing clinician 0.43 [0.09, 1.96]
Nonclinician researcher Reference
Constant 1.69 [0.72, 3.94]
Agree or strongly agree that health plans and funding agencies should use a higher LARC placement goal
Odds ratio 95% CI
Age (years) b40 1 [0.35, 2.88]
40s Reference
50+ 0.95 [0.30, 3.04]
Sex Male 5.12 [1.65, 15.85]
Female Reference
Researcher type LARC placing clinician 0.59 [0.23, 1.52]
Non-LARC placing clinician 0.62 [0.13, 3.06]
Nonclinician researcher Reference
Constant 0.55 [0.23, 1.32]
Agree or strongly agree that health plans and funding agencies should use financial incentives to encourage clinicians to place LARC methods
Odds ratio 95% CI
Age (years) b40 1.74 [0.47, 6.45]
40s Reference
50+ 1.48 [0.38, 5.72]
Sex Male 4.29 [1.31, 14.06]
Female Reference
Researcher type LARC placing clinician 0.86 [0.30, 2.47]
Non-LARC placing clinician 0.33 [0.03, 3.21]
Nonclinician researcher Reference
Constant 0.15 [0.05, 0.47]
Agree or strongly agree that it is appropriate for programs to pay women to use a LARC method
Odds ratio 95% CI
Age (years) b40 1.53 [0.29, 8.19]
40s Reference
50+ 0.19 [0.02, 2.27]
Sex Male 4.37 [0.74, 25.74]
Female Reference
Researcher type LARC placing clinician 0.64 [0.13, 3.15]
Non-LARC placing clinician 1.49 [0.14, 15.85]
Nonclinician researcher Reference
Constant 0.08 [0.02, 0.37]
a With less than 5% or more than 95% agreement on statements related to public assistance limiting benefits, corrections agencies reducing jail time, all
methods of contraception available for free or free LARC methods but not other methods, we had insufficient variation to conduct multivariate analyses for
these outcomes.
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Choice Project of Saint Louis (75% or more would use a
LARC method). In a multivariate linear regression model of
LARC projections, there were no significant differences by
age group, gender or researcher type (see Fig. 1).In the open responses, respondents raised questions about
the timeframe for increased adoption, pointing out that it
would take time to change the conversation around
contraception, “time is needed for people to feel it’s a
‘go-to’ method” reported a nonclinician researcher. Another
549D.G. Foster et al. / Contraception 92 (2015) 543–552nonclinician researcher reported that “many female sterili-
zations could be replaced by IUDs and implants to avoid
surgery, lower costs and better serve women.” Others
mentioned the need for cultural changes and engagement
with community leaders to improve the reputation of LARC.
For example, a nonclinician researcher wrote, “we need a
reproductive justice approach to LARC that starts with
women’s right to decide what’s best for them and right to
science-based, unbiased information about all contraceptive
methods. We need to engage women of color who are leaders
in reproductive justice work and community partners.”
3.3. Attitudes toward incentives to provide LARC methods
Our data reflect a range of opinions about incentives for
providers to place LARC methods. Support for policies
decreased as the placement rate goal increased or financial
incentives were added. The mean score for support of health
plans or funding agencies using a minimum threshold (such
as 1%) for LARC placement was just above neutral (0.17 on
a scale where 0 is neither disagree nor agree and 1 is agree).
Half (50%) of participants agreed or strongly agreed that a
minimum threshold goal was appropriate to confirm that
LARC methods are available; one third (34%) disagreed or
strongly disagreed with minimum threshold goals. We find
no statistically significant differences by age group, gender
or researcher type in support for a minimum threshold in a
multivariate model (see Table 3).
On average, support for a placement rate goal that is
higher than 1% was slightly lower than neutral (−0.14 on a
scale where −1 is disagree and 0 is neither disagree nor
agree). Over one third (38%) of participants reported that a
higher placement goal would be appropriate to encourage
clinicians to place more LARC; 45% disagreed. In a
multivariate logistic regression predicting agreement or
strong agreement with higher placement goals, we find that
men had five times higher odds of supporting higher
placement goals than women (odds ratio=5.12, 95% CI
[1.65, 15.85] (see Table 4)) but there were no differences by
researcher type or age group. A total of 30% of women and
two thirds of men agreed or strongly agreed with using a
higher placement goal. The mean suggested placement goal
among respondents who agreed with the use of higher
placement goals was 20%; 40% said “10% or less.” Three
quarters recommended “under 25%.” All suggested that
placement rates were 50% or lower.
Support for financial incentives was closer to disagree than
neutral on average (−0.70 on a scalewhere−1 is disagree and 0
is neutral). Only one in five (22%) agreed that it was
appropriate to use financial incentives to encourage clinicians
to place LARCmethods. More than half (62%) disagreed. In a
logistic regression predicting agreement or strong agreement
with financial incentives, we find that men had four times
higher odds of supporting financial incentives for providers
than women (odds ratio=4.29, 95% CI [1.31, 14.05]) but there
were no differences by researcher type or age group. A total of16%ofwomen and 43%ofmen agreed or strongly agreedwith
the use of financial incentives for providers.
In the comments section for opinions about provider
incentives, several respondents pointed out that the current
system has financial disincentives to providing LARC and
that greater payment is needed to cover the time and effort it
takes to place a LARC method. Several participants wrote
that populations and preferences differ from facility to
facility so it would be difficult to decide on an appropriate
placement goal or benchmark. The concern raised in most of
the free text comments was concern about potential coercion.
Some suggested that the ethical approach is financial
incentives for training on LARC provision and counseling
but not provision. For example, a nonclinician researcher
wrote “incentives could be given for offering LARC to
women…but obviously choosing a birth control method is a
very personal choice for the patient. Providers should not
pressure patients or only offer LARC in an attempt to
increase their paycheck, which is what could happen.”
Another concern expressed by the respondents was that
financial incentives would result in overzealous promotion
and reduce the credibility of providers. A clinician who
places LARC wrote “[I] strongly disagree on the use of
provider financial incentives; this will cause unconscious
coercion among providers to provide LARC. We know from
providers and their interactions with pharma[ceutical]
companies that something as small as a free pen does
influence them to dispense medication that may not be in line
with the patient’s best interests. Doing this with LARC will
have the same effect and will turn women off of LARC
and us.”
3.4. Attitudes toward incentives for women to use
LARC methods
There was almost no support for policies that incentivize
women to use LARC methods. Ninety-eight percent of
respondents disagreed or strongly disagreed with a policy to
restrict public assistance benefits for women who do not use
LARC methods (2% were neutral). The mean score
approached strongly disagree (−1.82 on a scale where −2
is strongly disagree and −1 is disagree). Ninety-two percent
were opposed to corrections agencies offering reduced jail
time for women who agree to use a LARC method (mean
score −1.67).
In contrast, respondents expressed strong support for
making all methods of contraception available for free for
women receiving public assistance (97% agreed or strongly
agreed and 3% were neutral; mean score 1.83 where 1 is
agree and 2 is strongly agree). This support was contingent
on making all methods available for free and not just LARC
methods (91% oppose covering only LARC methods; 5%
were neutral and 4% support covering only LARC methods;
mean score −1.53). On the final question about whether it is
appropriate to pay women to use a LARC method, over three
quarters (77%) of respondents were opposed; 14% were
neutral; 9% agreed with such a policy and none strongly
550 D.G. Foster et al. / Contraception 92 (2015) 543–552agreed (mean score −1.24). We found no differences by age,
gender or researcher type in a multivariate models predicting
agreement with financial incentives for women to use
LARC methods.
In the comments section about incentives for women,
several respondents clarified that free contraception should
not be limited to women receiving public assistance. A
clinician who places LARC wrote, “I agree that women
receiving public assistance should have access to all methods
of contraception for free because I think all women should
have access to all methods for free. These women are no
different.” Some respondents posited that LARC use will
increase without resorting to incentives. The vast majority of
responses noted that any incentives to use LARC were
potentially coercive. For example, a clinician placing LARC
wrote “it would be disturbing to see us go back to previous,
coercive, racist (since minority women are more likely to be
on public assistance) policies as the ones described here.
Yes, ALL forms of contraception should be available to ALL
women regardless of socioeconomic, incarceration status.
Whether or not a woman decides to get pregnant should not
impact her ability to get help from the government or her
sentencing.” Many respondents expressed revulsion at these
policies, writing words like “odious,” “very disturbing” and
“wrong.” The words “coercion” or “coercive” were put
forward in 22 separate comments to describe policies to
incentivize women (8) and providers (14).4. Discussion
Findings from this study reveal that clinical and social
science LARC experts project substantial increases in LARC
use in the US — at least a doubling of the current rate — if
current barriers to method provision and adoption are
removed. However, while the LARC experts we surveyed
recognize the promise of LARC methods to better meet
women’s contraceptive needs, they anticipate that most
women will not choose LARC methods. Even in the absence
of existing barriers to LARC use, experts on average expect
that fewer than a third of women will choose these methods.
With a minority of women using LARC, reducing
unintended pregnancy rates will depend on innovations in
the delivery of other methods of contraception, such as
over-the-counter access to the pill or dispensing a 1-year
supply of contraceptives, and the development of new
contraceptive methods that meet women’s needs.
These LARC experts identify the cost of LARC devices
as the greatest barrier to LARC use among women — a
barrier that is already being reduced, at least in part, by new
ACA contraceptive coverage requirements [36] and the
introduction of new, lower-cost devices, such as Liletta®, to
the market [37]. However, even when cost barriers are
removed, programs that offer no-cost contraception may
continue to face multiple challenges in providing LARC,
including unavailability of methods onsite, lack of trainedproviders and cumbersome clinic protocols that will need to
be addressed to ensure that women have access to a full
range of contraceptive options [32,34]. The next three most
commonly identified barriers — lack of information about
safety and acceptability, fear of side effects and concern
about having the device placed — might be addressed with
improvements in patient education. Innovations in patient
education, such as development of structured counseling
protocols, videos or apps, may help to improve patients’
understanding and reduce their concerns about LARC
[38,39].
About half of respondents cited the lack of trained
primary care providers as a significant barrier to LARC
provision. As more women gain access to contraception
through the ACA, it is anticipated that primary care settings,
such as community health centers or federally qualified
health centers (FQHCs), will need to meet many women’s
family planning needs. While FQHCs are required to provide
family planning services [40], they face greater barriers in
providing LARC than family planning providers [32].
Training primary care providers in the latest contraceptive
standards and equipping them to integrate contraceptive
counseling into the routine medical visit, while reducing the
need for multiple visits to obtain LARC, will be important to
ensure patient access to these methods.
Given the potential benefits of using LARC methods and
the large number of barriers women face to access LARC
relative to other methods, it is not surprising that experts in
this study support efforts to ensure the availability of LARC
methods in the US. However, their enthusiasm for policies to
encourage LARC use was tempered by concern about the
potential coercive effect of specific policies. While half of
the experts surveyed support the practice of health plans or
funding agencies setting minimum threshold policies to
ensure availability of LARC methods, fewer supported
LARC placement goals. The majority of experts disagreed or
strongly disagreed with using financial or other incentives to
encourage providers to place LARC methods and nearly all
opposed financial incentives to women to use LARC. There
was widespread agreement that all methods, including
LARC, should be available for free but overwhelming
disagreement with a scheme that would make only LARC
methods, and not other methods, available at no cost.
We found a surprising lack of difference of opinion on
these policy questions by respondent age or whether they
were a practicing clinician, nonpracticing clinician or a
nonclinician researcher. We did find significant differences
by gender in attitudes toward two LARC promotion policies:
placement goals and financial incentives for providers. It is
possible that the more cautious approach to incentives
among women is due to personal experience with contra-
ceptive use and a greater acknowledgment of the possibility
of coercion. Unfortunately, we had too few participants of
any one nonwhite racial/ethnic group to look at how opinions
differ by race/ethnicity and too much variation in responses
between the respondents of color to group all nonwhites
551D.G. Foster et al. / Contraception 92 (2015) 543–552together. The underrepresentation of ethnic minorities
among LARC researchers, illustrative of a widespread
problem in academic medicine [41], may limit the research
questions, policies and priorities in this field and is
particularly problematic given the history and politics
of contraception.
This study aimed to assess the opinions and attitudes of
thought leaders in LARC delivery. Our response rate (68%)
was high for a voluntary survey of busy professionals.
Despite the relatively high response rate, it is possible that
nonresponse was related to assumptions about the motiva-
tions of the two researchers who sent out the invitation to
participate. Both authors have published on the superior cost
effectiveness of IUDs [42,43]. Although Dr. Foster’s
primary work is on the consequences of abortion and the
effectiveness of family planning programs, she has published
on self-removal of IUDs [44,45] and the importance of user
control as a feature of contraceptive methods [46]. Dr. Biggs
has published on provider practices and attitudes about
LARC. Knowing the authors or the authors’ views may have
influenced some potential participants to participate or not
participate or may have introduced social desirability bias.
Efforts to increase LARC use will be more successful if
providers and women feel confident that LARC policies and
practices meet the dual goals of increasing access to LARC
methods and protecting women’s reproductive autonomy.
To accomplish this, we need reasonable expectations for use,
the availability of low- or no-cost devices and investments in
provider training and patient education rather than financial
or other incentives for providers or women. The promise of
LARC methods will be realized when they are available for
free and presented as options alongside other contraceptive
methods, allowing women to choose the method that best
meets their individual needs.
Acknowledgements
The authors thank Drs. Christine Dehlendorf, Jenny
Higgins and E. Bimla Schwarz for their advice about policies
to include in the opinion survey.
References
[1] Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Nelson
AL, Cates W, Kowal D, & Policar M, editors. Contraceptive
Techology. NewYork, NY: Ardent Media; 2011.
[2] UN Department of Economic and Social Affairs, Population Division.
Levels and trends of contraceptive use as assessed in 2002; 2006 [ http://
www.un.org/esa/population/publications/wcu2002/WCU2002_Report.
pdf (accessed October 13, 2015)].
[3] Daniels K, Daugherty J, Jones J. Current contraceptive status among
women aged 15–44: United States. NCHS Data Brief 2011–
2013;2014(173):1–8.
[4] Arias RD. Compelling reasons for recommending IUDs to any woman
of reproductive age. Int J Fertil Womens Med 2002;47(2):87–95.
[5] Morgan KW. The intrauterine device: rethinking old paradigms.
J Midwifery Womens Health 2006;51(6):464–70.[6] Speidel JJ, Harper CC, Shields WC. The potential of long-acting
reversible contraception to decrease unintended pregnancy. Contra-
ception 2008;78(3):197–200.
[7] Pickle S, Wu J, Burbank-Schmitt E. Prevention of unintended
pregnancy: a focus on long-acting reversible contraception. Prim
Care 2014;41(2):239–60.
[8] Blumenthal PD, Voedisch A, Gemzell-Danielsson K. Strategies to
prevent unintended pregnancy: increasing use of long-acting reversible
contraception. Hum Reprod Update 2011;17(1):121–37.
[9] Trussell J, Henry N, Hassan F, Prezioso A, Law A, Filonenko A.
Burden of unintended pregnancy in the United States: potential savings
with increased use of long-acting reversible contraception. Contracep-
tion 2013;87(2):154–61.
[10] ACOG Committee Opinion No. 392, December 2007. Intrauterine
device and adolescents. Obstet Gynecol 2007;110(6):1493–5.
[11] American College of Obstetricians Gynecologists. ACOG Committee
Opinion no. 450: increasing use of contraceptive implants and
intrauterine devices to reduce unintended pregnancy. Obstet Gynecol
2009;114(6):1434–8.
[12] American College of Obstetricians Gynecologists. Adolescents and
long-acting reversible contraception: implants and intrauterine devices,
Committee Opinion No. 539. Obstet Gynecol 2012;120(4):983–8.
[13] Curtis KM, Bauer U, Barfield W. US Selected Practice Recommen-
dations for Contraceptive Use, 2013 Adapted from the World Health
Organization Selected Practice Recommendations for Contraceptive
Use, 2nd Edition. MMWR Recomm Rep 2013;62(5):1–9.
[14] Centers for Disease Control and Prevention (CDC). U.S. Medical
Eligibility Criteria for Contraceptive Use, 2010. MMWR 2010;59:1–5.
[15] Committee on Adolescence. Contraception for adolescents. Pediatrics
2014;134(4):e1244–56.
[16] Ricketts S, Klingler G, Schwalberg R. Game change in Colorado:
widespread use of long-acting reversible contraceptives and rapid
decline in births among young, low-income women. Perspect Sex
Reprod Health 2014;46(3):125–32.
[17] Biggs MA, Arons A, Turner R, Brindis CD. Same-day LARC insertion
attitudes and practices. Contraception 2013;88(5):629–35.
[18] Biggs MA, Rocca CH, Brindis CD, Hirsch H, Grossman D. Did
increasing use of highly effective contraception contribute to declining
abortions in Iowa? Contraception 2015;91(2):167–73.
[19] Peipert JF, Madden T, Allsworth JE, Secura GM. Preventing
unintended pregnancies by providing no-cost contraception. Obstet
Gynecol 2012;120(6):1291–7.
[20] Lewis C, Darney P, Thiel de Bocanegra H. Intrauterine contraception:
impact of provider training on participant knowledge and provision.
Contraception 2013;88(2):226–31.
[21] Harper CC, Rocca CH, Thompson KM, Morfesis J, Goodman S,
Darney PD, et al. Reductions in pregnancy rates in the USA with long-
acting reversible contraception: a cluster randomised trial. Lancet
2015;386:562–8.
[22] Finer LB, Jerman J, Kavanaugh ML. Changes in use of long-acting
contraceptive methods in the United States, 2007–2009. Fertil Steril
2012;98(4):893–7.
[23] Branum A, Jones J. Trends in long-acting reversible contraception use
among U.S. women aged 15–44. NCHS Data Brief 2015;188:1–8.
[24] Stern LF, Simons HR, Kohn JE, Debevec EJ, Morfesis JM, Patel AA.
Differences in contraceptive use between family planning providers
and the U.S. population: results of a nationwide survey. Contraception
2015;91(6):464–9.
[25] United Nations Department of Economic and Social Affairs Population
Division: World Contraceptive Patterns 2012; 2012 [POP/DB/CP/
Rev2012].
[26] GomezAM, Fuentes L, Allina A.Women or LARC first? Reproductive
autonomy and the promotion of long-acting reversible contraceptive
methods. Perspect Sex Reprod Health 2014;46(3):171–5.
[27] Higgins JA. Celebration meets caution: LARC’s boons, potential
busts, and the benefits of a reproductive justice approach. Contracep-
tion 2014;89(4):237–41.
552 D.G. Foster et al. / Contraception 92 (2015) 543–552[28] Dehlendorf C, Bellanca H, Policar M. Performance measures for
contraceptive care: what are we actually trying to measure?
Contraception 2015;91(6):433–7.
[29] Gold RB. Guarding against coercion while ensuring access: a delicate
balance. Guttmacher Policy Rev 2014;17(3):8–4.
[30] Luchowski AT, Anderson BL, Power ML, Raglan GB, Espey E,
Schulkin J. Obstetrician-gynecologists and contraception: practice and
opinions about the use of IUDs in nulliparous women, adolescents and
other patient populations. Contraception 2014;89(6):572–7.
[31] Morse J, Freedman L, Speidel JJ, Thompson KM, Stratton L, Harper
CC. Postabortion contraception: qualitative interviews on counseling
and provision of long-acting reversible contraceptive methods.
Perspect Sex Reprod Health 2012;44(2):100–6.
[32] Biggs MA, Harper CC, Brindis CD. California family planning health
care providers’ challenges to same-day long-acting reversible
contraception provision. Obstet Gynecol 2015;126(2):338–45.
[33] Harper CC, BlumM, de Bocanegra HT, Darney PD, Speidel JJ, Policar
M, et al. Challenges in translating evidence to practice: the provision of
intrauterine contraception. Obstet Gynecol 2008;111(6):1359–69.
[34] Biggs MA, Harper CC, Malvin J, Brindis CD. Factors influencing the
provision of long-acting reversible contraception in California. Obstet
Gynecol 2014;123(3):593–602.
[35] HathawayM, Torres L, Vollett-Krech J, Wohltjen H. Increasing LARC
utilization: any woman, any place, any time. Clin Obstet Gynecol
2014;57(4):718–30.
[36] Sonfield A, Tapales A, Jones RK, Finer LB. Impact of the federal
contraceptive coverage guarantee on out-of-pocket payments for
contraceptives: 2014 update. Contraception 2015;91(1):44–8.
[37] Eisenberg DL, Schreiber CA, Turok DK, Teal SB,Westhoff CL, Creinin
MD, et al. Three-year efficacy and safety of a new 52-mg levonorgestrel-
releasing intrauterine system. Contraception 2015;92(1):10–6.[38] Gilliam ML, Martins SL, Bartlett E, Mistretta SQ, Holl JL.
Development and testing of an iOS waiting room “app” for
contraceptive counseling in a Title X family planning clinic. Am J
Obstet Gynecol 2014;211(5):481.e481–8.
[39] Davidson AS, Whitaker AK, Martins SL, Hill B, Kuhn C, Hagbom-Ma
C, et al. Impact of a theory-based video on initiation of long-acting
reversible contraception after abortion. Am J Obstet Gynecol
2015;212(3):310.e311–7.
[40] Lesnewski R, Maldonado L, Prine L. Community health centers’ role
in family planning. J Health Care Poor Underserved
2013;24(2):429–34.
[41] Whittaker JA, Montgomery BL, Martinez Acosta VG. Retention of
underrepresented minority faculty: strategic initiatives for institutional
value proposition based on perspectives from a range of academic
institutions. J Undergrad Neurosci Educ 2015;13(3):A136–45.
[42] Foster DG, Biggs MA,Malvin J, Bradsberry M, Darney P, Brindis CD.
Cost-savings from the provision of specific contraceptive methods in
2009. Womens Health Issues 2013;23(4):e265–71.
[43] Foster DG, Rostovtseva DP, Brindis CD, Biggs MA, Hulett D, Darney
PD. Cost savings from the provision of specific methods of
contraception in a publicly funded program. Am J Public Health
2009;99(3):446–51.
[44] Foster DG, Grossman D, Turok DK, Peipert JF, Prine L, Schreiber CA,
et al. Interest in and experience with IUD self-removal. Contraception
2014;90(1):54–9.
[45] Foster DG, Karasek D, Grossman D, Darney P, Schwarz EB. Interest in
using intrauterine contraception when the option of self-removal is
provided. Contraception 2012;85(3):257–62.
[46] Lessard LN, Karasek D, Ma S, Darney P, Deardorff J, Lahiff M, et al.
Contraceptive features preferred by women at high risk of unintended
pregnancy. Perspect Sex Reprod Health 2012;44(3):194–200.
